Expression of musashi-2 gene in leukemia stem cells from acute myeloid leukemia patients.
10.7534/j.issn.1009-2137.2014.05.009
- Author:
Ai-Fang YE
1
;
Yi-Xiang HAN
1
;
Sheng-Hui ZHANG
2
;
Hai-Ying LI
1
;
Chi-Qi CHEN
1
;
Jian-Bo WU
1
Author Information
1. Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China.
2. Key Laboratory of Biochemistry and Molecular Biology, Fudan University Medical College, Shanghai 200433, China. E-mail: shenghuizhang1@126.com.
- Publication Type:Journal Article
- MeSH:
Flow Cytometry;
Gene Expression Regulation, Leukemic;
Humans;
Leukemia, Myeloid, Acute;
genetics;
Neoplastic Stem Cells;
metabolism;
RNA, Messenger;
RNA-Binding Proteins;
genetics
- From:
Journal of Experimental Hematology
2014;22(5):1235-1238
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to detect the expression of Musashi-2 (Msi2) in acute myeloid leukemia (AML) and investigate the relationship between Msi2 and other clinical parameters, especially CD34. A total RNA was extracted from bone marrow of newly diagnosed AML patietns. The Msi2 mRNA expression in newly diagnosed AML patients was detected with real-time fluorescence quantitative RT-PCR. The expression level of CD34 in above-menthioned patients was detected by flow cytometry (FCM). The relationship between the expression of Msi2 mRNA and clinical outcome in AML patients was analysed. The results showed that (1)the expression of Msi2 mRNA in newly diagnosed AML patients was much higher than that in healthy volunteers (P < 0.05) , especially in M1, M4 and M5 patients; (2)the expression level of Msi2 did not correlate with age, sex, white blood cell count of peripheral blood, AML1/ETO and PML/RARa fusion gene (P > 0.05); (3) Msi2 expression level in patients with CD34(+) cells was significantly higher than that in patients with CD34(-) cells (P < 0.05). It is concluded that the Msi2 mRNA expresses in leukamia stem cells, the high expression of Msi2 mRNA has been found in newly diagnosed AML patients, especially in M1, M4 and M5 patients, the high expression also has been observed in patients with CD34(+).
